Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215423 · ClinicalTrials.gov registry record · Phase 2
Study in Patients With COPD
A Phase 2 study, sponsored by Dey.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00215423: Completed Phase 2 study, sponsored by Dey.
NCT00215423 is a Phase 2 study that has completed, run by Dey. The registered enrollment target is 49 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00215423, a Phase 2 study, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug
Interventions
- DRUG Formoterol Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
What the finished NCT00215423 record still lists
NCT00215423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which Formoterol Fumarate is the first listed.
NCT00215423 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00215423 about?
NCT00215423 is a clinical study titled "Study in Patients With COPD". The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug
What is the current status of trial NCT00215423?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00215423?
The interventions under investigation include: Formoterol Fumarate (DRUG).
Who is sponsoring clinical trial NCT00215423?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00215423's enrollment target sits among peer trials
49 1261st of 2000 higher than 736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer